Drug Database
Back to search

Poland· PL-100340632

Busulfan Accord

A busulfan product containing busulfanum, registered in Poland by Accord Healthcare Polska Sp. z o.o.. The same ATC class is registered in 15 of our 19 countries.

ATC L01AB01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBusulfan AccordATCL01AB01REGISTER NO.PL-100340632PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about busulfanumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Busulfan is registered in 15 of 19 countries.

Countries holding a registration under ATC L01AB01 (busulfan), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search busulfan products by name

Busulfan · ATC L01AB01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Busulfanum
Manufacturer
Accord Healthcare Polska Sp. z o.o.
Country
Poland (PL)
ATC code
L01AB01
ATC class
Busulfan
Defined daily dose
0.224 g, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05055565729373
  • gtin
    05055565729380

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

245 interactions on record for busulfan.

Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check busulfan against other medicinesHow interaction checks work

Busulfan · interactions on record

245 records

  • 34 severe
  • 141 moderate
  • 16 minor
  • 54 info

Most severe, free to view

  • Nalidixic acidJ01MB02severe
  • MetronidazoleJ01XD01severe
  • ThiotepaL01AC01severe
  • CladribineL01BB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Busulfan in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All busulfan products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

  • Austria · Busulfan Accord, Myleran
  • Belgium · Myleran
  • Czechia · Myleran
  • Germany · Busulfan Accord, Busulfan Koanaa
  • Denmark · Busulfan Zentiva
  • Estonia · Myleran
  • Spain · Busulfano Accord, Busulfano Aspen
  • France · Busulfan Accord, Busulfan Koanaa
  • United Kingdom (Northern Ireland) · Busulfan Accord, Busulfan Aspen Pharma Trading Limited
  • Greece · Busulfan Bioars
  • Croatia · Busulfan Pliva
  • Hungary · Busulfan Accord, Busulfan Teva
  • Ireland · Myleran
  • Iceland · Busulfan Fresenius Kabi, Myleran
  • Italy · Busulfan Accord, Busulfan Tillomed
  • Liechtenstein · Busulfan Fresenius Kabi
  • Lithuania · Myleran
  • Luxembourg · Myleran
  • Netherlands · Busulfan Teva, Myleran
  • Norway · Busulfan Fresenius Kabi
  • Portugal · Bussulfano Accord, Myleran
  • Romania · Busulfan Accord, Myleran
  • Sweden · Busulfan Zentiva, Myleran
  • Slovakia · Myleran

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/561ea6fd-9db6-4408-8e55-1457566b50dd
GET /v1/drugs/561ea6fd-9db6-4408-8e55-1457566b50dd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "6 mg/ml",
  "packaging": "05055565729373 ¦ Rpz ¦ 117084\n1 fiol. 10 ml\n05055565729380 ¦ Rpz ¦ 117085\n8 fiol. 10 ml",
  "substance": "Busulfanum 6 mg/ml",
  "common_name": "Busulfanum",
  "pl_product_id": "100340632",
  "pozwolenie_nr": "23361",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about busulfan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console